Ocugen (OCGN) Free Cash Flow Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -3.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.17% |
| Dec 31, 2025 | 2.82% |
| Sep 30, 2025 | 7.45% |
| Jun 30, 2025 | 7.65% |
| Mar 31, 2025 | -7.31% |
| Dec 31, 2024 | 7.23% |
| Sep 30, 2024 | -12.49% |
| Jun 30, 2024 | 17.47% |
| Mar 31, 2024 | -25.53% |
| Dec 31, 2023 | -45.70% |
| Sep 30, 2023 | -84.71% |
| Jun 30, 2023 | -91.22% |
| Mar 31, 2023 | -61.81% |
| Dec 31, 2022 | -20.75% |
| Sep 30, 2022 | -97.19% |
| Jun 30, 2022 | -59.74% |
| Mar 31, 2022 | -80.23% |
| Dec 31, 2021 | -67.09% |
| Sep 30, 2021 | -10.46% |
| Jun 30, 2021 | -62.29% |
| Mar 31, 2021 | -62.97% |
| Dec 31, 2020 | -0.53% |
| Sep 30, 2020 | 22.34% |
| Jun 30, 2020 | 18.33% |
| Mar 31, 2020 | 14.06% |
| Dec 31, 2019 | -14.03% |
| Sep 30, 2019 | 27.07% |
| Jun 30, 2019 | 21.08% |
| Mar 31, 2019 | 30.20% |
| Dec 31, 2018 | 26.89% |
| Sep 30, 2018 | 5.94% |
| Jun 30, 2018 | 13.12% |
| Mar 31, 2018 | 31.00% |
| Dec 31, 2017 | 11.42% |
| Sep 30, 2017 | -11.44% |
| Jun 30, 2017 | -0.89% |
| Mar 31, 2017 | -12.83% |